
    
      This study is designed to assess the safety, tolerability and efficacy of TOP1630 ophthalmic
      solution in subjects with Dry Eye Syndrome.

      Eligible subjects will be randomized double masked to either TOP1630 or placebo.

      Part 1 (time frame 12 days) comprises assessment of safety, tolerability and ocular comfort.

      Part 2 (time frame 35 days) comprises assessment of safety, tolerability and efficacy
    
  